>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • SYNH +24.6%, AAXN +22.5%, ETSY +16.2%, OCN +14.2%, TIVO +12.9%, (also announces plan to explore all alternatives to maximize shareholder value), ENPH +11.1%,WTW +10.3%, TAST +9.3%, BKNG +8.4%, RRD +8.2%, FRAN +7.1%, MGIC +7%, CSU +6.6%, CGBD +6.5%, SBLK +6.1%, OAS +5.8%, ATSG +5.8%, VEEV +5.5%, CHS +5%, DAR+4.8%, RP +3.7%, MASI +3.4%, PNM +3.4%, HEI +3.1%, AKAO +3.1%, MTZ +3%, SUPN +3%, UNVR +3%, ATUS +2.8%, FSS +2.5%, UPL +2.4%, FRO +2%, IMAX +1.9%, ESRX+1.8%, RDC +1.8%, XOG +1.7%, DEPO +1.6%, STWD +1.6%, GBT +1.3%, WP +1.3%, MITT +1%, PEN +1%, ODP +1%, .
M&A news:
  • STB +24% (Student Transportation to be acquired by a group of investors led by CDPQ for US$7.50 per common share in cash)
  • PHH +23.7% (PHH Corp to be acquired by Ocwen (OCN) in an all cash transaction valued at $360 million, or $11.00 per fully-diluted share)
  • OCN +14.2% (PHH Corp to be acquired by Ocwen (OCN) in an all cash transaction valued at $360 million, or $11.00 per fully-diluted share)
  • SGYP +8.5% (acquires exclusive Canadian rights to FDA-Approved Trulance from Synergy Pharmaceuticals)
  • MON +0.9% (Monsanto merger with Bayer (BAYRY) said to be set to be approved by the EU, subject to conditions, according to Reuters)
Other news:
  • CODX +14.7% (positive results from Co-Primers Technology in multiplex test for SNP detection)
  • MTP +11.1% (European Medicines Agency has granted Orphan Drug Designation for its advanced liver cancer drug candidate MTD119)
  • HTBX +6.7% (announces 'positive' interim data from its Phase 2 clinical trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer)
  • MBVX +5.6% (reports positive safety results from initial cohort of MVT-1075 Radioimmunotherapy Phase 1 Trail for the treatment of Pancreatic, Colon and Lung Cancers)
  • ECYT +3.6% (proposed public offering of common stock)
  • EXPE +2.6% (following BKNG results)
  • NMIH +1.5% (prices 3.7 mln shares of common stock at $19.75 per share)
  • DPW +1.2% (reschedules investor webcast to March 15 at 5pm ET - originally set for February 21 - focus of the webcast will be on MTIX)
  • STMP +1% (hired former Mattel Chief Technology Officer Jonathan Bourgoine as its new Chief Technology Officer)
  • BEDU +1% (prices 10 mln ADS's at $19.00 per ADS)
  • SHPG +1% (receives FDA acceptance of BLA for Cal-PEG)
  • BIDU +0.8% (Baidu.com's iQiyi unit filed for $1.5 bln IPO late yesterday)
Analyst comments:
  • MELI +3.8% (upgraded to Overweight from Neutral at JP Morgan)
  • CVX +1.1% (upgraded to Buy from Neutral at BofA/Merrill)
  • ADM +0.9% (upgraded to Buy from Neutral at Buckingham Research)
  • PM +0.7% (upgraded to Buy from Neutral at Citigroup)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • FTR -24.8%, (also suspends the quarterly cash dividend on the common stock), ELF -10.8%, TSRO -9.2%, VRX -8.3%, ACAD -7.6%, BGFV -7.6%, BGS -7.1%, MNKD -7%,LOW -6.7%, GTE -6.1%, ALRM -5.8%, EOG -5.6%, PZZA -5.1%, GGB -4.7%, ROG -4.5%, SSYS -4%, HTZ -3.9%, TA -3.8%, JONE -3.1%, SSW -3.1%, CYH -2.9%, MHLD -2.8%,TDOC -2.7%, TNET -2.6%, JAZZ -2.6%, WDAY -2.3%, VTVT -2.3%, (also files for $250 mln share Class A common stock shelf offering ), CROX -2.3%, DXCM -2.2%, SQ-1.7%, DRYS -1.1%, FGEN -0.8%
Other news:
  • ATRA -6.6% (proposed offering of $150 mln in shares of common stock)
  • CELG -6.1% (receives Refusal to File letter from the FDA regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis)
  • GM -1.5% (General Motors announced 40 mln share secondary offering of common stock by the UAW Retiree Medical Benefits Trust; GM intends to repurchase a portion of the shares being offered)
  • DISCA -1.3% (still checking - DISCA / SNI set election deadline - expect to consummate the transactions contemplated by the Merger Agreement on March 6, 2018)
  • DM -0.8% (files for $500 mln common units representing limited partner interests shelf offering)
Analyst comments:
  • ALV -1.5% (downgraded to Sell from Hold at Societe Generale)

TEchCrunch : Here and Naver Labs ink robotics deal to map indoor spaces

Here and Naver Labs ink robotics deal to map indoor spaces

Your trip through the airport or train station may soon become a little more crowded — not with people, but with robots, busily scanning and plotting the space so that one day, even more of their cousins can zip around with your luggage and Shake Shack orders.

Here, the mapping company majority-owned by Audi, BMW and Daimler, has entered a robotics partnership with Naver Labs, part of Naver — the company that created and spun out the messaging app Line, to expand autonomous indoor mapping coverage: Naver Labs will be using its robots, its image-recognition and its indoor mapping tech to help build 3D indoor maps for the Here platform, specifically of high-traffic spots like airports and train stations.

Here tells me that the first indoor maps that they will work on together are of airports in Korea, where Naver is headquartered, before expanding to other markets and venues.

The collaboration will start off with Here using Naver Labs’ M1, a 3D indoor mapping robot that uses laser scanners and cameras, to capture information. Around the airport, another Naver robot — aptly called “Around” — will circulate to keep information updated. These maps in turn will be sold on to companies that are building apps for autonomous services and consumers to use when in the venues.

While a lot of 3D mapping services has been building detailed databases of outdoor spaces — not just for mapping apps but anything that might need location-based information, such as an immersive game — the focus for companies like Google, Apple, and Here has expanded indoors, too — for those games, for navigation apps, but also to fill the need of all autonomous, moving devices to have accurate information about the spaces in which they operate: think beyond mobile apps to self-driving luggage and caddies or other logistical and location-based features.

In January, Here announced the acquisition of Micello — which had built up both a database of and platform for building indoor maps — also to further this effort.

Here and Naver are not disclosing the financial terms of the deal “yet”, a spokesperson said. So it’s unclear if Naver will invest in Here, or vice-versa, as part of the deal.

Here already has other tech companies strategically investing in it alongside those big three carmakers: last year, Intel revealed it was putting an undisclosed amount into the company to take a 15 percent stake, and other shareholders include Pioneer, Continental and Bosch . But an attempt by Navinfo, Tencent and GIC to take a 10 percent stake was quashed by the US government over security concerns.

Rivals have criticised Here for being built on a lot of legacy IP — it got its start years ago as Navteq — that is in need of better updating. While its automaker owners clearly have a strong route for doing that outdoors — in addition to satellite imagery, there are their vehicles themselves, which can be used to ingest as well as use location data — this is a sign of how Here plans to fill the gap indoors.

“Our collaboration with Naver Labs supports Here Technologies’ strategy to provide world-class mapping and location services both indoors and outdoors,” said Edzard Overbeek, CEO of Here, in a statement. “We’re excited to leverage advanced robotics technology in the development of indoor maps, and look forward to exploring further collaboration opportunities with Naver in the future.”

For Naver, it will mean an expansion of its business outside of its region, diversification that its tried with mixed success up to now.

“Together with Here Technologies, Naver Labs looks forward to bringing the capabilities of our scalable and semantic indoor mapping technology (SSIM) to the global market,” said Chang Song, CEO of Naver Labs.

>>> Celgene: Color on FDA refusal to file (RTF) letter on ozanimod for relapsi

Celgene: Color on FDA refusal to file (RTF) letter on ozanimod for relapsing forms of multiple sclerosis (95.78)
  • SunTrust downgrades to HOld, tgt to $106 from $139. While mgmt. stated that (1) the refusal to file (RTF; see draft guidance HERE) has "nothing to do with [ozanimod's] core efficacy or safety profile" and (2) there is no indication for another pivotal study (particularly as ozanimod's Phase III SUNBEAM and RADIANCE trials were both conducted under a SPA), they believe CELG may need to run additional or complete ongoing nonclinical and clinical pharmacology studies to ensure the drug achieves target exposure in all relevant populations. While they continue to view ozanimod's efficacy and safety profile as favorable for an eventual approval, the RTF could result in a 24-month or longer delay for ozanimod's RMS launch. Hence, they are conservatively moving the U.S. launch of ozanimod to 2021 (vs. prior 4Q18). Also, given that generics for competitor Novartis' (NVS, NR) Gilenya (a SP1R modulator) are expected to be on the market by the time ozanimod is launched, which is likely to increase competition, they are reducing ozanimod's peak sales potential in RMS to $1.3B (from $2.1B). Their overall peak sales for the drug in UC/RMS goes to ~$3.5B (from ~$5B).
  • Mizuho: Given the lack of detail provided on last night's call in terms of what the FDA needs to see for a resubmission and subsequent approval, the implied move in POS / stock price may be warranted, but until the company can meet with the FDA and then provide a clear roadmap to approval, the odds of success (primarily in MS) will likely be debated in their view, and also presents another opportunity for value investors who have been sidelined on the stock to take a look at the name. Recall, S1P1 (mechanism of action) is already a validated mechanism by the way of NVS's Gilenya, and the data thus far has shown CELG's Ozanimod to be essentially a safer Gilenya. They think resubmission could occur mid-2018, with approval in mid-2019, assuming a standard review. CELG also reffirmed 2020 guidance.
  • Stifel lowers their CELG tgt to $128 from $130 Celgene provided an Ozanimod regulatory update that it received a Refusal-To-File letter from the FDA. The agency determined that certain pharmacology sections in the NDA filing were unsatisfactorily completed to currently permit review. From the initial feedback the company has received, Celgene believes it does not need to conduct a pivotal study and noted that supplemental clinical pharmacology data generation was already under way. While they acknowledge yesterday's news adds uncertainty to the timelines, they still believe Ozanimod's pivotal safety/efficacy data is sufficient for approval (discussed herein). They expect the end result in yesterday's news will be a few months' delay in ozanimod's approval and launch into an increasingly competitive relapsing MS market (Gilenya goes generic February 2019). As a result, they are pushing out Ozanimod revenues by ~six months and reducing 2019/2020 estimates slightly.
  • CELG -6% just above Feb 9/3+ year lows premarke

FT : China manufacturing gauge suffers sharpest fall in 6 years

China manufacturing gauge suffers sharpest fall in 6 years
Unexpectedly severe slowdown leaves index near zero-growth level, hitting mining shares

China’s official gauge of manufacturing activity suffered its largest fall since 2011 in February, an unexpectedly sharp slowdown that left it near the zero-growth level.

The manufacturing purchasing managers’ index published by China’s National Bureau of Statistics on Wednesday dropped to 50.3, down a point from January and the largest fall in more than six years. The fall marked the gauge’s nearest brush with the 50-point mark that separates growth from contraction since August 2016.

The figure was stark enough to unnerve European-listed mining stocks, which depend upon China for a significant part of their revenues.

Mining stocks took the biggest toll on London’s FTSE 100 in morning trade, with losses of more than 2 per cent for Rio Tinto, Glencore, BHP Billiton and Anglo American. The Stoxx mining index, which tracks the sector across the region, fell 2.3 per cent against a decline of just 0.3 per cent for the Europe-wide Stoxx 600.

A median forecast from economists polled by Reuters ahead of the PMI data had predicted only a fractional slowdown: none of the 28 forecasts for February had pencilled in a reading below 51 for the gauge, which is based on a survey of larger and predominantly state-run companies.

China’s statistics bureau attributed the slowdown to the lunar new year holiday, when migrant workers return to their home villages and output typically dips. In 2017 the holiday stretched from the end of January to early February, while this year’s holiday fell entirely in February, making for an unfavourable comparison.


However, the downward move was outsize for the usually incremental series, marking the sharpest fall since a 1.4 point drop in late 2011 that pushed the gauge into contractionary territory.

“The lower PMI readings for February may be partly due to Chinese new year, since seasonal adjustments may not fully iron out the impact in year-to-year shifts in the timing of the holiday,” said Julian Evans-Pritchard, senior China economist at Capital Economics. “But even if we account for such volatility by averaging across the first two months of the year, the data still point to a clear slowdown in early 2018.”

Betty Wang, senior China economist for ANZ, suggested authorities’ crackdown on heavy polluters “also played an important role in dampening the headline numbers on top of the holiday effect”. But she added that while the drive’s impact on manufacturing activity would probably last for another couple of months, it was unlikely to have an impact on policy direction.

A variety of measures pointed to softer expansion, with a sub-index for growth in manufacturing output down almost 3 points at 50.7, while that for new orders fell 1.6 points to 51. A sub-index for export orders fell half a point to 49, signalling contraction in foreign demand.


Meanwhile, a gauge that tracks factory gate prices fell 2.6 points to 49.2, signalling the first instance of producer price deflation since June 2017 ending a seven-month rising streak.

China’s official non-manufacturing PMI was also down in February, dropping almost one point to 54.4 — a four-month low. A key sub-index for services sector growth fell 0.6 points to 53.8, while that for construction dropped 3 points to 57.5, suggesting softer growth was not limited to factories in February.

The next signpost for China’s manufacturers will be Thursday’s Caixin-Markit manufacturing PMI, an independent gauge that focuses on smaller, privately owned manufacturers and acts as a cross-check on the official series.

>>> US early premarket gappers

Early premarket gappers
Gapping up:
  • PHH +23.2%, STB +23.1%, AAXN +18.2%, ETSY +16.5%, ENPH +11.8%, OCN +11.6%,TIVO +10.7%, WTW +9.9%, RRD +8.2%, BKNG +7.8%, CSU +6.6%, CGBD +6.5%, SBLK+6.1%, FRAN +6.1%, TAST +5.5%, RRC +5.2%, ATSG +4.8%, DAR +4.8%, VEEV +4.7%,OAS +4.7%, ESRX +3.9%, RP +3.7%, MASI +3.4%, HEI +3.1%, MTZ +3%, SUPN +3%,CWH +2.9%, ATUS +2.8%, EXPE +2.7%, ALB +2.2%, IMAX +1.9%, RDC +1.8%, XOG+1.7%, DEPO +1.6%, STWD +1.6%, BEDU +1.5%, FRO +1.5%, ECYT +1.4%, GBT+1.3%, WP +1.3%, DPW +1.2%, NBR +1.2%, STMP +1%, MITT +1%, AKAO +1%, PEN+1%
Gapping down:
  • FTR -28.1%, TSRO -9.2%, ELF -8.5%, BGS -8%, BGFV -7.6%, ACAD -7.4%, CELG-7.2%, MNKD -7%, LOW -6.7%, VRX -6.5%, EOG -6.3%, GTE -6.1%, PZZA -6%, ALRM-5.8%, SSYS -5.1%, GGB -4.7%, HTZ -4.5%, ROG -4.5%, TDOC -4%, TA -3.8%, CROX-3.6%, ATRA -3.4%, JONE -3.1%, SSW -3.1%, CYH -2.9%, MHLD -2.8%, TNET -2.6%,JAZZ -2.6%, DISCA -2.5%, WDAY -2.5%, VTVT -2.3%, DXCM -2.2%, SQ -1.8%, GM-1.4%, DRYS -1.1%